Huntington's disease: pathogenesis, diagnosis and treatment.

Shaping the role of mitochondria in the pathogenesis of Huntington's disease. EMBO J (2012) 1.11

Mitophagy in neurodegeneration and aging. Front Genet (2012) 0.95

Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology (Berl) (2003) 0.92

Saccadic impairments in Huntington's disease. Exp Brain Res (2008) 0.89

Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases. Int J Mol Sci (2014) 0.84

Huntington's disease: review and anesthetic case management. Anesth Prog (1998) 0.83

Plants and phytochemicals for Huntington's disease. Pharmacogn Rev (2013) 0.77

Optical coherence tomography findings in Huntington's disease: a potential biomarker of disease progression. J Neurol (2015) 0.76

Huntington's Disease: An Immune Perspective. Neurol Res Int (2011) 0.76

Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci (1986) 18.17

A polymorphic DNA marker genetically linked to Huntington's disease. Nature (1984) 16.71

The functional anatomy of basal ganglia disorders. Trends Neurosci (1989) 12.28

Glutamate neurotoxicity and diseases of the nervous system. Neuron (1988) 8.26

Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol (1985) 7.93

Functional mapping of the human visual cortex by magnetic resonance imaging. Science (1991) 6.93

The psychological consequences of predictive testing for Huntington's disease. Canadian Collaborative Study of Predictive Testing. N Engl J Med (1992) 5.51

Huntington's chorea in Michigan. I. Demography and genetics. Am J Hum Genet (1958) 4.14

Huntington disease: genetics and epidemiology. Am J Hum Genet (1984) 2.81

Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A (1988) 2.78

Huntington's disease. Pathogenesis and management. N Engl J Med (1986) 2.77

Increased rate of suicide among patients with Huntington's disease. J Neurol Neurosurg Psychiatry (1984) 2.31

Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature (1986) 2.29

Huntington's chorea. J Med Genet (1966) 2.26

Selective sparing of a class of striatal neurons in Huntington's disease. Science (1985) 2.16

Socio-psychiatric consequences of Huntington's disease. Br J Psychiatry (1970) 2.12

Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature (1976) 2.08

Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain. N Engl J Med (1973) 2.06

Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. Hum Mol Genet (1993) 2.00

Huntington disease-linked restriction fragment length polymorphism localized within band p16.1 of chromosome 4 by in situ hybridization. Am J Hum Genet (1986) 1.98

Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol (1988) 1.79

The association of affective disorder with Huntington's disease in a case series and in families. Psychol Med (1983) 1.65

Maternal transmission in Huntington's disease. Lancet (1983) 1.64

Huntington's chorea. Investigation into the prevalence of this disease in the area covered by the North East Metropolitan Regional Hospital Board. Brain (1967) 1.60

Ethics of a predictive test for Huntington's chorea. Br Med J (Clin Res Ed) (1982) 1.58

Procedural learning and neostriatal dysfunction in man. Brain (1988) 1.57

Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk. Am J Med Genet (1986) 1.55

PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol (1986) 1.53

Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci (1990) 1.51

Predictive testing for Huntington disease: II. Demographic characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates. Am J Med Genet (1989) 1.46

Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J Neurosci (1991) 1.45

Psychiatric syndromes in Huntington's disease. Am J Psychiatry (1983) 1.38

Positron emission tomography in the early diagnosis of Huntington's disease. Neurology (1986) 1.33

Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J Neuropathol Exp Neurol (1991) 1.27

Biochemical abnormalities in Huntington's chorea brains. Neurology (1974) 1.27

Evidence of presymptomatic cognitive decline in Huntington's disease. J Clin Exp Neuropsychol (1992) 1.27

Patterns of inheritance of the symptoms of Huntington's disease suggestive of an effect of genomic imprinting. J Med Genet (1991) 1.25

Abnormal ocular motor control in Huntington's disease. Neurology (1983) 1.23

Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci Lett (1991) 1.21

Are there neuropsychologic manifestations of the gene for Huntington's disease in asymptomatic, at-risk individuals? Arch Neurol (1990) 1.20

Presymptomatic neuropsychological impairment in Huntington's disease. Arch Neurol (1988) 1.19

Huntington's dementia. Clinical and neuropsychological features. Arch Gen Psychiatry (1978) 1.10

Comparison of the neuropsychological deficits associated with early and advanced Huntington's disease. Arch Neurol (1978) 1.06

Huntington's chorea: neglected opportunities for preventive medicine. Lancet (1983) 1.04

Cortical glucose metabolism in Huntington's disease. Neurology (1992) 1.03

Nature and distribution of brain lesions in rats intoxicated with 3-nitropropionic acid: a type of hypoxic (energy deficient) brain damage. Acta Neuropathol (1987) 1.01

A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease. Ann Neurol (1990) 1.01

Clinical correlates of dementia and disability in Huntington's disease. J Clin Neuropsychol (1984) 1.00

Functional neuronal replacement by grafted striatal neurones in the ibotenic acid-lesioned rat striatum. Nature (1984) 0.99

Intrastriatal transplantation of cross-species fetal striatal cells reduces abnormal movements in a primate model of Huntington disease. Proc Natl Acad Sci U S A (1992) 0.97

Isoniazid therapy of Huntington disease. Neurology (1979) 0.97

The EEG in Huntington's chorea: a clinical and neuropathological study. J Neurol Neurosurg Psychiatry (1972) 0.96

Clinical and magnetic resonance features of the classic and akinetic-rigid variants of Huntington's disease. Arch Neurol (1993) 0.96

A double-blind clinical trial of isoniazid in Huntington disease. Neurology (1982) 0.95

Neuropathology of Huntington's chorea. Studies of the ventrobasal complex of the thalamus. Neurology (1976) 0.95

Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology (1988) 0.94

Genetic testing for Huntington's disease--a family issue. N Engl J Med (1992) 0.94

Development of neuropsychological deficits in Huntington's disease. Arch Neurol (1983) 0.93

Reduced regional cerebral blood flow in Huntington's disease studied by SPECT. J Neurol Neurosurg Psychiatry (1992) 0.93

Mitochondrial impairment reduces the threshold for in vivo NMDA-mediated neuronal death in the striatum. Exp Neurol (1993) 0.92

Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. Neurosci Lett (1992) 0.91

A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol (1989) 0.90

DNA-testing for Huntington's disease in The Netherlands: a retrospective study on psychosocial effects. Am J Med Genet (1992) 0.90

Patterns of intellectual deficit in Huntington's disease. J Clin Neuropsychol (1982) 0.90

Prefrontal cortical blood flow and cognitive function in Huntington's disease. J Neurol Neurosurg Psychiatry (1988) 0.89

Graft-induced behavioral recovery in an animal model of Huntington disease. Proc Natl Acad Sci U S A (1986) 0.89

Psychological dysfunction accompanying subcortical dementias. Annu Rev Med (1988) 0.89

Language functions in Huntington's disease. Brain (1988) 0.87

ATP deficits and neuronal degeneration induced by 3-nitropropionic acid. Ann N Y Acad Sci (1992) 0.86

Treatment of Huntington disease with gamma-acetylenic GABA an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration. Neurology (1981) 0.85

Patterns of neuropsychological test performance in Huntington's disease. J Nerv Ment Dis (1975) 0.85

Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects. J Neurol Sci (1980) 0.85

Neuro-psychiatric aspects of Huntington's disease. Confin Neurol (1969) 0.85

Cerebellar atrophy in Huntington's disease. J Neurol Sci (1981) 0.84

Stereotactic technique and pathophysiological mechanisms of neurotransplantation in Huntington's chorea. Stereotact Funct Neurosurg (1992) 0.84

Relationship between motor and cognitive disorders in Huntington's disease. J Neurol (1988) 0.83

Huntington's disease: treatment with muscimol, a GABA-mimetic drug. Ann Neurol (1978) 0.82

Protocol for genetic testing in Huntington disease: three years of experience in Minnesota. Am J Med Genet (1991) 0.81

Age dependence of striatal neuronal death caused by mitochondrial dysfunction. Neuroreport (1993) 0.81

Increase in kynurenic acid in Huntington's disease motor cortex. J Neurochem (1989) 0.80

Correlates of early disability in Huntington's disease. Ann Neurol (1986) 0.80

THIP treatment of Huntington's disease. Neurology (1983) 0.79

Neuronal organization of fetal striatal grafts in kainate- and sham-lesioned rat caudate nucleus: light- and electron-microscopic observations. J Neurosci (1988) 0.79

Huntington's disease: effect of cysteamine, a somatostatin-depleting agent. Neurology (1986) 0.78

Ethical issues in genetic testing for Huntington's disease: lessons for the study of familial cancers. Dis Markers (1993) 0.78

Neural grafts and pharmacological intervention in a model of Huntington's disease. Brain Res Bull (1990) 0.77

Huntington's disease as a model for mood disorders. Clues from neuropathology and neurochemistry. Mol Chem Neuropathol (1990) 0.77

Huntington's disease: correlations of mental status with chorea. Biol Psychiatry (1987) 0.76

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol (1998) 9.33

Characterization of urease from Campylobacter pylori. J Clin Microbiol (1988) 5.57

Pyelonephritogenic Escherichia coli and killing of cultured human renal proximal tubular epithelial cells: role of hemolysin in some strains. Infect Immun (1990) 4.94

Ruffles induced by Salmonella and other stimuli direct macropinocytosis of bacteria. Nature (1993) 4.30

Identification of a Salmonella typhimurium invasion locus by selection for hyperinvasive mutants. Proc Natl Acad Sci U S A (1992) 3.79

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry (2000) 2.66

Genetic and biochemical diversity of ureases of Proteus, Providencia, and Morganella species isolated from urinary tract infection. Infect Immun (1987) 2.52

Non-invasive Salmonella typhimurium mutants are avirulent because of an inability to enter and destroy M cells of ileal Peyer's patches. Mol Microbiol (1997) 2.21

Cloning of urease gene sequences from Providencia stuartii. Infect Immun (1986) 2.06

Salmonella pathogenicity island 2-encoded type III secretion system mediates exclusion of NADPH oxidase assembly from the phagosomal membrane. J Immunol (2001) 2.04

Detection of multiresistant Salmonella typhimurium DT104 using multiplex and fluorogenic PCR. Mol Cell Probes (1999) 1.64

Interactions of the invasive pathogens Salmonella typhimurium, Listeria monocytogenes, and Shigella flexneri with M cells and murine Peyer's patches. Infect Immun (1998) 1.58

Hha is a negative modulator of transcription of hilA, the Salmonella enterica serovar Typhimurium invasion gene transcriptional activator. J Bacteriol (2001) 1.52

Tardive dyskinesia: legal and preventive aspects. Can J Psychiatry (1990) 1.47

Eye tracking dysfunction is associated with partial trisomy of chromosome 5 and schizophrenia. Arch Gen Psychiatry (1988) 1.43

Hypergammaglobulinemia in a dog. J Am Vet Med Assoc (1995) 1.39

Endoscopic and surgical retrieval of fishhooks from the stomach and esophagus in dogs and cats: 75 cases (1977-1993) J Am Vet Med Assoc (1995) 1.39

Clozapine: current status and role in the pharmacotherapy of schizophrenia. Can J Psychiatry (1996) 1.38

Transcriptional organization and function of invasion genes within Salmonella enterica serovar Typhimurium pathogenicity island 1, including the prgH, prgI, prgJ, prgK, orgA, orgB, and orgC genes. Infect Immun (2000) 1.35

Partial trisomy chromosome 5 cosegregating with schizophrenia. Lancet (1988) 1.35

A set of ftsZ mutants blocked at different stages of cell division in Caulobacter. Mol Microbiol (2001) 1.33

Identification and characterization of mutants with increased expression of hilA, the invasion gene transcriptional activator of Salmonella typhimurium. FEMS Immunol Med Microbiol (2000) 1.32

Fis, a DNA nucleoid-associated protein, is involved in Salmonella typhimurium SPI-1 invasion gene expression. Mol Microbiol (2001) 1.30

Preparing and retaining rural physicians through medical education. Acad Med (1999) 1.23

Identification of diminished tissue culture invasiveness among multiple antibiotic resistant Salmonella typhimurium DT104. Microb Pathog (2000) 1.21

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol (1988) 1.19

Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry (1978) 1.19

Mutation of the htrB gene in a virulent Salmonella typhimurium strain by intergeneric transduction: strain construction and phenotypic characterization. J Bacteriol (1997) 1.19

Morganella morganii urease: purification, characterization, and isolation of gene sequences. J Bacteriol (1990) 1.18

Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord (1997) 1.18

Complications and results of phacoemulsification performed by residents. J Cataract Refract Surg (1995) 1.16

Salmonella enterica serovars gallinarum and pullorum expressing Salmonella enterica serovar typhimurium type 1 fimbriae exhibit increased invasiveness for mammalian cells. Infect Immun (2000) 1.15

Salmonella pathogenicity island 2-encoded proteins SseC and SseD are essential for virulence and are substrates of the type III secretion system. Infect Immun (2001) 1.14

Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry (1980) 1.09

Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo (1995) 1.08

Early diagnosis of water intoxication by monitoring diurnal variations in body weight. Am J Psychiatry (1987) 1.07

Death attributed to ventricular arrhythmia induced by thioridazine in combination with a single Contac C capsule. Can Med Assoc J (1978) 1.07

The neurohypophyseal hormones vasopressin and oxytocin. Precursor structure, synthesis and regulation. Biol Chem Hoppe Seyler (1986) 1.06

Identification of Listeria monocytogenes in vivo-induced genes by fluorescence-activated cell sorting. Infect Immun (2001) 1.04

Urease activity of Proteus penneri. J Clin Microbiol (1987) 1.04

Psychiatric morbidity associated with early clinical diagnosis of Huntington disease in a predictive testing program. J Clin Psychiatry (1988) 1.03

Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. J Neurol Neurosurg Psychiatry (1991) 0.98

Location analysis of DNA-bound proteins at the whole-genome level: untangling transcriptional regulatory networks. Bioessays (2001) 0.96

Schizophrenia as dopamine-deficiency disease. Lancet (1978) 0.96

An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states. Psychopharmacology (Berl) (1995) 0.94

Heterogeneity in Alzheimer's disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles. J Neurol Neurosurg Psychiatry (1992) 0.94

Transdermal nicotine: single dose effects on mood, EEG, performance, and event-related potentials. Pharmacol Biochem Behav (1999) 0.94

Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam. Neurology (1991) 0.92

Thrombosis: the major Hickman catheter complication in patients with solid tumor. Chest (1989) 0.92

Interaction of ginseng with phenelzine. J Clin Psychopharmacol (1987) 0.91

Dendritic localization of rat vasopressin mRNA: ultrastructural analysis and mapping of targeting elements. Eur J Neurosci (1997) 0.91

Regional cerebral blood flow and cognitive function in Huntington's disease and schizophrenia. A comparison of patients matched for performance on a prefrontal-type task. Arch Neurol (1990) 0.90

Rat vasopressin and oxytocin genes are linked by a long interspersed repeated DNA element (LINE): sequence and transcriptional analysis of LINE. DNA Cell Biol (1991) 0.89

Early epithelial invasion by Salmonella enterica serovar Typhimurium DT104 in the swine ileum. Vet Pathol (2002) 0.89

Early onset of tardive dyskinesia: case report. Am J Psychiatry (1979) 0.89

Mode structure of coupled L3 photonic crystal cavities. Opt Express (2011) 0.88

Laryngeal tuberculosis: a case report. J Natl Med Assoc (1979) 0.88

Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86. Arch Neurol (1986) 0.87

GABA-agonist therapy for Alzheimer's disease. Clin Neuropharmacol (1986) 0.86

Cortical glucose utilization patterns in primary degenerative dementias of the anterior and posterior type. Arch Gerontol Geriatr (1987) 0.86

Rapidly progressive Alzheimer's disease. Lancet (1989) 0.85

Characteristics of clients with schizophrenia who express certainty or uncertainty about continuing treatment with depot neuroleptic medication. Arch Psychiatr Nurs (1997) 0.85

Electroencephalographic coherence in Alzheimer's disease: comparisons with a control group and population norms. J Geriatr Psychiatry Neurol (2000) 0.84

Effects of abdominal insufflation with nitrous oxide on cardiorespiratory measurements in spontaneously breathing isoflurane-anesthetized dogs. Am J Vet Res (1993) 0.84

GIF-DB, a WWW database on gene interactions involved in Drosophila melanogaster development. Nucleic Acids Res (1997) 0.84

Quo vadis: extrasomatic targeting of neuronal mRNAs in mammals. Mol Cell Endocrinol (1997) 0.83

A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease. Can J Neurol Sci (1997) 0.82

Expression of the vasopressin and oxytocin genes in human hypothalami. FEBS Lett (1985) 0.82

No response to high-dose muscarinic agonist therapy in Alzheimer's disease. Neurology (1988) 0.82

Nicotine and smoker status moderate brain electric and mood activation induced by ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist. Pharmacol Biochem Behav (2006) 0.81

Clozapine in the treatment of refractory schizophrenia: Canadian policies and clinical guidelines. Can J Psychiatry (1992) 0.81

192 IgG-saporin lesion of basal forebrain cholinergic neurons in neonatal rats. Brain Res Dev Brain Res (1996) 0.80

Risperidone treatment of bipolar disorder. Can J Psychiatry (1997) 0.80

Outcome variables in presymptomatic individuals at higher risk of developing Alzheimer disease. Alzheimer Dis Assoc Disord (1996) 0.80

Nicotine and sensory memory in Alzheimer's disease: an event-related potential study. Brain Cogn (2002) 0.80

Polarized quantum dot emission from photonic crystal nanocavities studied under moderesonant enhanced excitation. Opt Express (2007) 0.80

Deprenyl in Parkinson's disease: mechanisms, neuroprotective effect, indications and adverse effects. Can J Neurol Sci (1992) 0.80

The functional neuroanatomy of Tourette's syndrome: an FDG-PET Study. II: Relationships between regional cerebral metabolism and associated behavioral and cognitive features of the illness. Neuropsychopharmacology (1995) 0.79

Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry (1994) 0.79

Clinical evaluation of a modified circumcostal gastropexy in dogs. J Am Vet Med Assoc (1999) 0.79

Acute nicotine effects on auditory sensory memory in tacrine-treated and nontreated patients with Alzheimer's disease: an event-related potential study. Pharmacol Biochem Behav (2002) 0.79

Observation of a near-threshold enhancement in the pp mass spectrum from radiative J/psi-->gammapp decays. Phys Rev Lett (2003) 0.79

Hepatic biopsy. Vet Clin North Am Small Anim Pract (1985) 0.79

Measurements of the cross section for e(+)e(-) --> hadrons at center-of-mass energies from 2 to 5 GeV. Phys Rev Lett (2002) 0.79

Evaluation of percutaneous gastrostomy as a technique for permanent gastropexy. Vet Surg (1997) 0.79

Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry (1992) 0.79

Pharmaco-EEG test dose response predicts cholinesterase inhibitor treatment outcome in Alzheimer's disease. Methods Find Exp Clin Pharmacol (2000) 0.79

Attentional deficits in Alzheimer's, Parkinson's, and Huntington's diseases. Acta Neurol Scand (1996) 0.78

Clinical trials in dementia: learning effects with repeated testing. J Psychiatry Neurosci (1991) 0.78

Quantitative electroencephalography in Alzheimer's disease: comparison with a control group, population norms and mental status. J Psychiatry Neurosci (2001) 0.78

Effects of haloperidol pretreatment on the smoking-induced EEG/mood activation response profile. Neuropsychobiology (2001) 0.78

Huntington's disease: effect of cysteamine, a somatostatin-depleting agent. Neurology (1986) 0.78

Effects of acute nicotine administration on cognitive event-related potentials in tacrine-treated and non-treated patients with Alzheimer's disease. Neuropsychobiology (2002) 0.78

Diagnosis and treatment of peritonitis caused by a larval cestode Mesocestoides spp., in a dog. Cornell Vet (1979) 0.78